These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 21599440

  • 1. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators.
    Abergel RJ, Raymond KN.
    Hemoglobin; 2011; 35(3):276-90. PubMed ID: 21599440
    [Abstract] [Full Text] [Related]

  • 2. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).
    Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, Shuh DK, Raymond KN.
    Health Phys; 2010 Sep; 99(3):401-7. PubMed ID: 20699704
    [Abstract] [Full Text] [Related]

  • 3. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators.
    Durbin PW.
    Health Phys; 2008 Nov; 95(5):465-92. PubMed ID: 18849679
    [Abstract] [Full Text] [Related]

  • 4. Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions.
    Kullgren B, Jarvis EE, An DD, Abergel RJ.
    Toxicol Mech Methods; 2013 Jan; 23(1):18-26. PubMed ID: 22957518
    [Abstract] [Full Text] [Related]

  • 5. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J, Obando D, Schipanski LG, Groebler LK, Witting PK, Kalinowski DS, Richardson DR, Codd R.
    J Med Chem; 2010 Feb 11; 53(3):1370-82. PubMed ID: 20041672
    [Abstract] [Full Text] [Related]

  • 6. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands.
    White DL, Durbin PW, Jeung N, Raymond KN.
    J Med Chem; 1988 Jan 11; 31(1):11-8. PubMed ID: 2826783
    [Abstract] [Full Text] [Related]

  • 7. New tris(hydroxypyridinones) as iron and aluminium sequestering agents: synthesis, complexation and in vivo studies.
    Chaves S, Marques SM, Matos AM, Nunes A, Gano L, Tuccinardi T, Martinelli A, Santos MA.
    Chemistry; 2010 Sep 10; 16(34):10535-45. PubMed ID: 20665585
    [Abstract] [Full Text] [Related]

  • 8. Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxyl-1-methyl-2(1H)-pyridinone ligands for in vivo plutonium(IV) chelation.
    Xu J, Kullgren B, Durbin PW, Raymond KN.
    J Med Chem; 1995 Jul 07; 38(14):2606-14. PubMed ID: 7629800
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hydroxypyri(mi)dine-based chelators as antidotes of toxicity due to aluminum and actinides.
    Santos MA, Esteves MA, Chaves S.
    Curr Med Chem; 2012 Jul 07; 19(17):2773-93. PubMed ID: 22455584
    [Abstract] [Full Text] [Related]

  • 11. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB, Richardson DR.
    Am J Hematol; 2003 Jul 07; 73(3):200-10. PubMed ID: 12827659
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers.
    Zhou T, Kong XL, Liu ZD, Liu DY, Hider RC.
    Biomacromolecules; 2008 May 07; 9(5):1372-80. PubMed ID: 18373358
    [Abstract] [Full Text] [Related]

  • 13. Design of iron chelators: syntheses and iron (III) complexing abilities of tripodal tris-bidentate ligands.
    d'Hardemare Adu M, Torelli S, Serratrice G, Pierre JL.
    Biometals; 2006 Aug 07; 19(4):349-66. PubMed ID: 16841245
    [Abstract] [Full Text] [Related]

  • 14. Selective chelation of Cd(II) and Pb(II) versus Ca(II) and Zn(II) by using octadentate ligands containing pyridinecarboxylate and pyridyl pendants.
    Ferreirós-Martínez R, Esteban-Gómez D, Platas-Iglesias C, de Blas A, Rodríguez-Blas T.
    Inorg Chem; 2009 Dec 07; 48(23):10976-87. PubMed ID: 19877597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
    Bernhardt PV, Chin P, Richardson DR.
    J Biol Inorg Chem; 2001 Oct 07; 6(8):801-9. PubMed ID: 11713687
    [Abstract] [Full Text] [Related]

  • 17. Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands.
    Uhlir LC, Durbin PW, Jeung N, Raymond KN.
    J Med Chem; 1993 Feb 19; 36(4):504-9. PubMed ID: 8386249
    [Abstract] [Full Text] [Related]

  • 18. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
    Bergeron RJ, Wiegand J, Weimar WR, Vinson JR, Bussenius J, Yao GW, McManis JS.
    J Med Chem; 1999 Jan 14; 42(1):95-108. PubMed ID: 9888836
    [Abstract] [Full Text] [Related]

  • 19. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Jan 14; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 20. New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation.
    Grazina R, Gano L, Sebestík J, Amelia Santos M.
    J Inorg Biochem; 2009 Feb 14; 103(2):262-73. PubMed ID: 19062099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.